NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
DESOXYN (methamphetamine hydrochloride) by Hikma is 12. Approved for methamphetamine use disorder. First approved in 1943.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DESOXYN is a methamphetamine hydrochloride oral extended-release tablet approved in 1943 for the treatment of methamphetamine use disorder. It works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their release into the extraneuronal space. The exact mechanism of therapeutic action remains incompletely understood.
LOE Approaching
Approaching loss of exclusivity with minimal linked job activity suggests a small, stable commercial footprint focused on regulatory compliance and specialty distribution.
Mechanism of Action
12. CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known. 12.2 Pharmacodynamics Amphetamines block the reuptake of norepinephrine and dopamine…
Worked on DESOXYN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.